Related Experiment Video

Updated: Aug 11, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

Deborah Choe1, Dongwon Choi1

  • 1Department of Surgery, Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States.

Frontiers in Oncology
|February 9, 2023
PubMed

Insights

Targeting the CD200/CD200R pathway can enhance anti-tumor immunity. This review explores CD200

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Immune checkpoints regulate immune responses to prevent self-damage.
  • Cancer utilizes immune checkpoints like CD200 to evade immune detection.
  • CD200 (a surface glycoprotein) interacts with CD200R to suppress immune cells in the tumor microenvironment.

Purpose of the Study:

  • To review the role of CD200 and its receptor (CD200R) in cancer immunity.
  • To explore strategies for targeting the CD200/CD200R pathway for cancer immunotherapy.
  • To discuss the expression and function of CD200 in various tissues relevant to cancer.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of CD200 and CD200R expression and function.
  • Summary of preclinical and clinical studies on CD200/CD200R blockade.

Main Results:

  • CD200 suppresses anti-tumor immune activity by engaging CD200R.
  • Targeting the CD200/CD200R pathway with antibodies or inhibitors boosts anti-tumor responses.
  • CD200 is expressed in the tumor microenvironment, blood endothelial cells, and lymph nodes.

Conclusions:

  • The CD200/CD200R pathway is a promising target for cancer immunotherapy.
  • Monoclonal antibodies and peptide inhibitors are effective strategies for blockade.
  • Further research and clinical studies are needed to optimize CD200-targeted therapies.
Keywords:
CD200CD200Rimmune-checkpointimmunotherapylymphaticstumor microenvironment

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

474
Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
616
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K